John M. Rothman
Corporate Officer/Principal bij TYME TECHNOLOGIES, INC.
Actieve functies van John M. Rothman
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
TYME TECHNOLOGIES, INC. | Corporate Officer/Principal | 19-08-2020 | - |
Loopbaan van John M. Rothman
Eerdere bekende functies van John M. Rothman
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
RACE ONCOLOGY LIMITED | Chief Tech/Sci/R&D Officer | - | 01-10-2019 |
AYALA PHARMACEUTICALS, INC. | Chief Operating Officer | 06-11-2009 | 09-12-2011 |
Chief Tech/Sci/R&D Officer | 01-03-2005 | 01-03-2013 | |
Corporate Officer/Principal | 09-12-2011 | 13-08-2012 |
Opleiding van John M. Rothman
Tulane University School of Medicine | Doctorate Degree |
Statistieken
Internationaal
Verenigde Staten | 4 |
Australië | 2 |
Operationeel
Corporate Officer/Principal | 2 |
Chief Tech/Sci/R&D Officer | 2 |
Chief Operating Officer | 1 |
Sectoraal
Health Technology | 4 |
Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
RACE ONCOLOGY LIMITED | Health Technology |
Bedrijven in privébezit | 2 |
---|---|
Tyme Technologies, Inc.
Tyme Technologies, Inc. Pharmaceuticals: MajorHealth Technology Tyme Technologies, Inc. operates as a biotechnology company, which engages in the development and commercialization of cancer therapies. It offers a clinical program named SM-88 which is a novel, oral, and monotherapy investigational agent that aims to disrupt the cancer cell's protein synthesis. The company was founded by Steve Hoffman and Michael Demurjian on November 22, 2011 and is headquartered in Bedminster, NJ. | Health Technology |
Advaxis, Inc.
Advaxis, Inc. Pharmaceuticals: MajorHealth Technology Advaxis, Inc. is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins. The firm has four franchises in various stages of clinical and pre-clinical development, namely: HPV-associated cancers, prostate cancer, neoantigen therapy and hotspot mutation therapy. The company was founded on June 5, 1987 and is headquartered in Princeton, NJ. | Health Technology |
- Beurs
- Insiders
- John M. Rothman
- Ervaring